MedTrace Logo

A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic Steatohepatitis

NCT06491576 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-07-09

No results posted yet for this study

Summary

This study is a single-center, randomized, double-blind, multiple ascending doses (MAD), placebo-controlled phase Ib/IIa clinical trial of BGT-002 Tablets in subjects with NASH to evaluate the safety, tolerability, pharmacokinetics (PK) and early pharmacodynamics (PD) of BGT-002 Tablets.

Conditions

  • NASH

Interventions

DRUG

BGT-002

taking the study drug orally

DRUG

Placebo

taking the placebo orally

Sponsors & Collaborators

  • Burgeon Therapeutics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ding Yanhua, Doctor · The First Hospital of Jilin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-21
Primary Completion
2024-03-04
Completion
2024-03-04

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06491576 on ClinicalTrials.gov